Mr. Mascarell will share the story of FineHeart at the Emerging Medtech Summit and will discuss strategic partnering and investment opportunities.
Arnaud started his career as a research engineer by Air Liquide in 1997. In 1998, he joined Medtronic where he had the opportunity to grow up in one of the world-class leading medtech. Senior executive with more than 17 years of experience managing sales, marketing, clinical, personal and merchandising at district and regional levels, Arnaud completed his academic training with a MBA from IAE Paris and a graduate from HEC Start Up. His taste for an entrepreneurial way let him co-found FineHeart in 2010.
Jeff is the co-founder and CEO of Embody, a medical device company developing collagen-based implants for tendon and ligament repair. Funded with over $15 million in non-dilutive funding from DARPA and a $3.6 million seed round in 2018, Embody is launching their Tapestry implant for Achilles and Rotator Cuff repair in 2020. In addition, Embody is developing the first collagen internal brace for ACL repair. The BioSpin platform technology is applicable to nerve, hernia, wound and cardiovascular applications.
Mr. Moran will attend the Emerging Medtech Summit to share the Motus GI story and discuss strategic partnering interests.
Tim has served as Chief Executive Officer since October 1, 2018. Prior to joining us, from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) (“ConvaTec”), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Covidien plc (“Covidien”), an Irish headquartered global health care products company and manufacturer of medical devices and supplies. While at Covidien, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. Mr. Moran was selected as a director because of his broad commercial experience and leadership in the medical technology sector.
Mr. Persson, a Swedish native, is a highly engaged and dedicated professional with 30 years of experience in Medical Device Industry. This includes General Management/Senior Leadership, International Sales and Marketing for the entire EMEA region. His commercial career within Medical Devices started regional sales with IVAC Inc. (today within Becton Dickinson). Since 2004 he has been in General Management roles, running direct affiliates in all aspects, including Sales, Marketing, Finance and related operations with companies such as Guidant (Director Marketing), Boston Scientific (GM Nordic Region), St Jude Medical (Director Marketing) Atos Medical (VP Sales and Marketing Europe).
Acarix has developed CADScor® System, a unique device with an acoustic sensor and algorithm to assess cardiac blood flow rapidly, safely and non-invasively. CADScor enables early rule out of symptomatic patients with suspected stable Coronary Artery Disease at point of care. CADScor® is in an early commercial phase in Europe. CADScor® is not approved for sales or commercial use within the USA. Acarix is a European based company with the Headquarter in Sweden, the approval process for the US market has been initiated recently.
Lorenzo Pradella, CEO & Co-Founder, GreenBone Ortho
At the Emerging Medtech Summit, Mr. Pradella will share the story of Greenbone Ortho and will be available to meet with potential investors and strategic partners.
Lorenzo has a Masters in Biological Sciences obtained at Università degli Studi di Milano with a Postgraduate Qualification in Pharmacology (Ph.D. equivalent). More then 25 years experiences in R&D, Business Development and Venture Capital. He held various senior positions in multinational companies such as Zambon Group SpA and Catalent Inc (formerly part of Cardinal Health Inc.). Lorenzo established licensing and acquisition deals with pharmaceutical, biotech and medtech companies. General Manager of Zcube srl (Research Venture of Zambon Group) from 2008 Lorenzo developed collaborations and investments with major universities hubs in Europe, United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), headquartered on the UCSF Mission Bay campus. Board member of biotech companies including SuppreMol GmbH when acquired by Baxter International Inc. for EUR 200 million in 2015. President of Italy HealthCare Licensing Group (ItalyHLG) 2010-2014 and Honorary President of the Business Development Academy since 2014.
Dushyanth lead the Acute Care Franchise within Dr. Reddy’s innovation business for several years. His responsibilities included the commercialization strategy of acute care products, which was the company’s highest value portfolio. He has had a proven track record in product conceptualization, invention, development, and licensing of products and devices across a number of therapeutic areas. He was responsible for the entire US branded sales and marketing organization, while also managing the corporate development and M&A function. He also held senior leadership roles across portfolio optimization, alliance management, and strategic planning.
Mr. Rocco will share the story of Biorez at the Emerging Medtech Summit and discuss strategic partnering and capital needs for the company.
Kevin is the CEO of Biorez, a medical device company developing bio-inductive implants for the $7B sports medicine market. He an experienced entrepreneur and expert in the field of tissue engineering, having raised $5M in seed funding for Biorez and coauthoring 19 peer-reviewed publications with 400+ citations. Previously, he was the first full-time engineer at STR during the first clinical investigation of a synthetic bio-inductive scaffold for ACL reconstruction, and was a part of the first clinical investigation of a bio-inductive scaffold as a vascular graft while a graduate student at Yale University.
Mr. Tas will share the story of SentiAR at the Emerging Medtech Summit and will provide updates on strategic partnering and investment opportunities.
Berk serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.
Amit will share the Promaxo story at the Emerging Medtech Summit and discuss partnering and fundraising updates.
Dr. Vohra is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit serves as a board member at Navaux and an advisor to Fanisko, Triocula and UnityDx.
Mr. Frick will share the story of ChemoTech at the Emerging Medtech Summit and will discuss investment and strategic partnering milestones.
ChemoTech is an R&D oriented publicly listed Life Science company based in Sweden. With more than 30 years of collected research and intellectual properties in the field of Electroporation and clinical research, ChemoTech has developed a new patent pending patient-specific Electroporation platform. A technology platform, called IQwave™, specifically designed to treat patients with larger bulk tumors that is difficult to treat with traditional cancer therapies. The first application built on this new innovative platform is already launched in India, Philippines and Kenya. The treatment protocol for this new device is called D-EECT and is used to treat none responsive Breast cancer, Head & Neck tumors and Sarcomas. Chemotech’s primary markets are India, South East Asia and Africa as patients in these markets often lack the availability to western cancer treatments combined with late diagnoses resulting in a high degree of incidence of large superficial tumor
About Mohan Born 1974 (Chengalpattu India) Education and experience: BA, Marketing and Management, Lund University. Co-Inventor of the D-EECT Technology and IQwave™ Next generation of Electroporation Devices 20 years’ experience as CEO, Marketing Manager and Board Director in life science industry having had positions at SYSMEX, OnMeD International, Arjo AB and Getinge AB. Current assignments: CEO & Board Director for Scandinavian ChemoTech AB Non-Profit assignments: Member of the Advisory Board for Billion Minds Foundation 2009-2014.
Mr. Khawar will share the story of Diality at Emerging Medtech Summit and will discuss partnering and investment opportunities.
Osman obtained his MD from the University of Glasgow and his MPH from Johns Hopkins. He is a Board-Certified nephrologist with a passion for Home Dialysis. He is an experienced Clinical researcher and entrepreneur who has run several businesses in the Dialysis industry including a Clinical Research company and several Dialysis Units in San Diego. He currently serves on the Palomar Health Foundation Board.
Rob will share his medical device investment interests at the Emerging Medtech Summit. Rob is CEO of Shoulder Innovations, Genesis Innovation and the Cultivate(MD) Fund where he focuses almost exclusively on early-stage medical device investments.
Rob has spent more than two decades bringing medical device technologies to market, including proprietary orthopedic materials.
Rob served at Tornier as Global Vice President, Research and Development, during which time Tornier grew from approximately $70M to $300M in annual revenues through organic growth of new products. He holds more than 30 issued or pending patents.
Peter brings more than 20 years of experience in the medical device and biopharmaceutical industry.
Prior to VCI, Peter served as the U.S. commercial vice president at Cordis. In addition, Peter has held senior sales roles at St. Jude Medical Corporation, AGA Medical Corporation and Covidien Healthcare (formerly Tyco Healthcare), among other leading health care companies.
Peter has proven experience driving commercial growth; building and leading diverse organizations of over 300 individuals, managing revenues exceeding $500 M and representing product offerings with C-level administrators. Peter received a Bachelor of Arts in Economics from the University of Massachusetts and completed the Columbia University Executive Management Program
Dr. Singh will share the Fist Assist story at the Emerging Medtech Summit and discuss partnering and fundraising needs.
Dr. Singh is a vascular/endovascular surgeon and entrepreneur with a strong understanding of current unmet clinical needs in vascular access markets. Founder of the Fist Assist Device which will help vein enlargement and fistula dilation.
Dr. Mitchell will share the story of Novuson at the Emerging Medtech Summit and will discuss their financing objectives and strategic partnering plans.
Dr. Mitchell is a graduate of the University of Washington and he has been designing biomedical instrumentation and devices for approximately 20 years. Dr. Mitchell has extensive experience in biomechanics (soft tissue and orthopedic), tissue engineering, instrumentation, electronics, and mechanical design.
While at the university, Dr. Mitchell managed and conducted research in multimillion dollar DARPA projects where he developed relationships with medical industry leaders. He has conducted research in biomechanics, tissue engineering, acoustic hemostasis and high intensity focused ultrasound (HIFU) for tumor treatment. Dr. Mitchell has been involved in helping HIFU gain recognition in the clinical setting and has led research teams in conducting application studies.
Dr. Wood has 20+ years of experience championing innovative clinical solutions to the marketplace, from concept to revenue.
Dr. Wood most recently held the position of Executive Vice President of Marketing and Technology for Vital Images, an innovative advanced visualization software company. Prior to Vital Images, Dr. Wood served as VP of marketing at R2 Technology (now Hologic), where she championed the development, regulatory approval and commercial release of the first FDA approved (PMA) software product for the automatic detection of lung nodules in both diagnostic and screening chest CT examinations.
Dr. Wood received her Ph.D. from the Johns Hopkins Medical Institutions, School of Hygiene and Public Health. Her Ph.D. work combined quantifying three-dimensional lung structure with changes in lung function using high-resolution CT imaging. She also holds a Master of Science degree in Biomedical Engineering from Duke University, and a Bachelor of Science in Engineering from the University of Maryland, College Park.
Dr. Wood has been issued six patents in the field of computer-aided detection and quantitative imaging; authored numerous book chapters, peer-reviewed papers, abstracts, and served as a speaker at numerous conferences in the area of three-dimensional imaging of the thorax, quantitative imaging and computer-aided detection.
Richard will share the story of SANA Health at the Emerging Medtech Summit and discuss partnering and investment objectives.
With an MBA in Healthcare and Entrepreneurial Studies from Wharton Business School, Hanbury went on to become the founder of Sana, a device that allows anyone to have deep relaxation and pain relief anywhere in an average of 8-10 mintues. Sana has decades of research and anecdotal data and has just complete their first internal controlled trial.
Mr. Borbath will share the story of Synergia Medical and the Emerging Medtech Summit and will discuss business, investment and partering updates.
Attila Borbath's M.Sc. in Business Administration and Engineering from the UCLouvain followed by the CEMS Master's in International Management naturally brought him to pave his professional way in a technological start-up in the finance sector for 10 years.
In parallel, he obtained his Airline Transport Pilot License. He was then convinced by the idea of joining an innovative technology start-up where he had the role of VP Sales and Marketing. In 2013, he moved to Synergia Medical that he co-founded. Well-travelled, multilingual and energetic, Attila has developed remarkable management, entrepreneurial, marketing, and business development skills.
Vadim Gurevich, CEO of GLW Medical Innovation (“GLW”), will represent his company at the Emerging Medtech Summit to discuss not only GLW’s latest R&D initiatives, but also their investment and strategic partnership needs. GLW is a medical device incubator focused on the design and development of cost-effective, high-margin implant and instrument solutions in various segments of the orthopedic market. They commercialize their products through exclusive distribution and education agreements with carefully selected sales organizations.
Mr. Gurevich has an extensive business career with over 19 years of leadership experience in medical technology. He has a documented record of success spanning a broad spectrum of disciplines, including orthopedic trauma, foot & ankle, urogynaecology, general surgery and neurosurgery with extensive M&A, licensing, and post-acquisition integration expertise. His career encompasses a series of executive and senior decision-making positions at Stryker Orthopaedics, Integra LifeSciences, Synovis Surgical (Baxter BioSurgery), and Gyrus Medical (Olympus).
Mr. Gurevich is also President & CEO of Novastep Inc., a US sales and distribution company focusing on products that treat conditions affecting the bones, joints, and soft tissues of the foot and ankle. He holds similar titles at Innov8ortho LLC, a sales distribution company specializing in musculoskeletal trauma injuries, specifically hip fracture care products.
Joseph McGinley, Founder & CEO, McGinley Orthopaedic Innovations
Dr. McGinley is a board-certified diagnostic radiologist. He holds a Bachelor's and Master's Degree in Mechanical Engineering and a PhD in Physiology from Temple University. He completed his residency and fellowship at Stanford University. Dr. McGinley is the founder and CEO of McGinley Orthopedic Innovations, LLC., as well as President and CEO of McGinley Manufacturing. He is also founder and CEO of McGinley Education, a company focusing on physician education of the latest techniques in interventional sports medicine. He currently holds over 100 patents.
Dr. Ben J. Lipps will share the story of Magforce at the Emerging Medtech Summit and will discuss strategic parntering and investment opportunities.
Dr. Lipps studied chemical engineering in the USA and earned his doctorate degree at the renowned Massachusetts Institute of Technology [MIT] in Boston. Dr Lipps was appointed to the Management Board of MagForce AG in September 2013.His career as manager began in the research departments at various companies, including at DOW Chemical, before switching to the Fresenius group in 1985, where he held various positions at Fresenius USA and Fresenius Medical Care North American until 2004. As Chairman of the Board, he led Fresenius Medical Care from 1999 to 2012 with a great deal of scientific and economic success.
Reinhard Krickl is the CEO of Phagenesis®. He has extensive experience in sales & marketing and new therapy development within the medical device industry, including 14 years as a “corporate entrepreneur” at Medtronic.
Alongside his industry experience he has a MBA and a MSc in Electrical and Electronics Engineering.
Lloyd Diamond, a US citizen, is a seasoned medtech executive and CEO with 25 years of disruptive technology commercialization experience in the life science industry. He most recently served as the CEO of Precise Light Surgical, a commercially ready medical device company in Silicon Valley. Prior to that, he was the CEO of Bonesupport AB, a European orthobiologic company, where he drove rapid market penetration in Europe and the US which led to a successful IPO on the NASDAQ OMX in Stockholm. Lloyd has first-hand experience in the ophthalmology segment as he was responsible for managing Lumenis’ global surgical and vision franchises. He has commercialized many other disruptive technology platforms including at Kyphon and Laserscope. Lloyd received a dual degree in Biochemistry and Marketing from Florida Atlantic University and an MBA from the Thunderbird School of Global Management at Arizona State University.
Bryan will share the Pristine Surgical story at the Emerging Medtech Summit and discuss partnering and fundraising updates.
Mr. Lord works with start-ups and investors to bring new med-tech, high-tech, clean-tech, and software products to the market and to help companies scale. He has experience as an executive, entrepreneur, advisor, deal facilitator, and investor.
Dr. Jabbarzadeh will share the story of Obsidio at Emerging Medtech Summit and will discuss investment and strategic partnering opportunities.
Dr. Jabbarzadeh is an academic entrepreneur with expertise in regenerative medicine and tissue engineering. He is an Associate Professor of Chemical and Biomedical Engineering and Director of Engineering Entrepreneurship at the University of South Carolina. His training includes a Ph.D. in Chemical Engineering from Drexel University, a Postdoctoral Fellowship in Bioengineering at the California Institute of Technology, and MBA in Finance at the University of Southern Carolina, Marshall School of Business. He has authored over 30 publications, 10 issued and pending patents, and delivered over 50 scientific talks. In recognition of his accomplishments, he has received the South Carolina InnoVision Award.
A global medical technology and health sciences executive, John Murphy has held leadership roles in large public companies, middle-market private equity businesses, and venture capital environments over the past 20 years. He holds graduate and undergraduate degrees in computer science and a MBA in international finance.
Dr. Marsteller is a serial medical device entrepreneur and co-innovator of the RadianceTx technology. He previously founded Salutaris Medical Devices, Inc. – invested in by ophthalmic market leader HOYA (7741:Tokyo, Market Cap $21B, $4.5B in annual sales). He is a Medical Doctor (University of Arizona College of Medicine), and physicist (Yale University Graduate School). Dr. Marsteller has Investment Banking experience as an Analyst at Lehman Brothers, and subsequently Morgan Stanley.
Derek DeScioli joined IntraOp Medical in 2015 as Vice President of Global Sales and assumed the position of CEO in 2018. Under his leadership, IntraOp is emerging as a leading innovator in the field of oncology with an expanded product portfolio, world-renowned clinical research partners, and a global team of professionals committed to improving care for cancer patients all over the world.
Prior to joining IntraOp, Derek was the Global Business Manager for 3M, where he led and launched 3 new-to-the-world technologies into the solar market, negotiated multi-year, multi-million dollar contracts with key accounts and was responsible for P&L with revenues in excess of $100M annually in his business unit. He was previously the VP of Operations and Supply Chain at Soliant Energy, a start-up company funded with $35M in private venture capital and DOE grants. A seasoned international sales and operations executive, Mr. DeScioli has held senior positions at Alpha Technologies (Enersys) and Astrodyne TDI in Shenzhen, China. Derek earned his Master’s Degree from Massachusetts Institute of Technology and holds a BS in Industrial Engineering from Rutgers University.